5221 RESULTS
Sort By:
RESEARCH NEWS 2019-08-02 Research News A study that followed more than 12,000 people for over 12 years adds significant weight to the idea that hemoglobin level is an important risk factor for Alzheimer’s and other dementias. Scientists led by M. Arfan Ikram at Erasmus Medical ...
RESEARCH NEWS 2019-08-02 Research News A GGGGCC hexanucleotide repeat expansion in intron 1 of the C9ORF72 gene causes familial amyotrophic lateral sclerosis and frontotemporal dementia. Aberrant translation of this expansion results in toxic poly-dipeptides that build up in the ...
RESEARCH NEWS 2019-08-01 Research News As microglia become more central to Alzheimer’s research, researchers are seeking better model systems to study their in vivo behavior. In culture, the cells rapidly alter their gene expression, and mouse microglia respond differently to ...
RESEARCH NEWS 2019-07-26 Research News According to an industry report today, AbbVie has called a halt to the Phase 2 trial of its anti-tau antibody ABBV-8E12 for progressive supranuclear palsy after it failed a futility analysis. AbbVie announced the termination during a ...
RESEARCH NEWS 2019-07-26 Research News The 2015 discovery of lymphatic vessels in the brain’s meninges threw open a door to seeing how this still-mysterious organ clears waste. Subsequent work showed that these vessels, which reside in the brain’s outermost membrane, the dura ...
CONFERENCE COVERAGE 2019-07-25 Conference Coverage Physical activity not only benefits the heart and the body, it may also shield the brain from the damaging effects of Aβ. That’s according to findings presented at the Alzheimer’s Association International Conference, held July 14–18 ...
CONFERENCE COVERAGE 2019-07-25 Conference Coverage Scientists are becoming more nuanced in how they use amyloid scans—not just to detect the presence of Alzheimer’s pathology, but also to pinpoint disease stage. At this year’s Alzheimer’s Association International Conference, held July ...
CONFERENCE COVERAGE 2019-07-21 Conference Coverage For neurodegenerative disease, the mantra is “go early,” based on the theory that intervention at prodromal stages may be most effective. Early detection could also help patients and families plan for the future, and avoid drugs ...
CONFERENCE COVERAGE 2019-07-20 Conference Coverage Research into dementia with Lewy bodies has lagged behind that for Alzheimer’s and Parkinson’s diseases, in part because DLB is difficult to identify, and less common. Many DLB trials fold because enrollment goals cannot be met. To ...
CONFERENCE COVERAGE 2019-07-19 Conference Coverage Lewy body dementia, the second-most-common progressive dementia after Alzheimer’s disease, receives relatively little attention and few research dollars, and often goes undiagnosed. Comedian Robin Williams, perhaps the most famous ...
CONFERENCE COVERAGE 2019-07-19 Conference Coverage Microglia not only gobble up detritus from dead cells, they also have a penchant for chowing down on live ones. At a Keystone joint symposia—Neurodegenerative Diseases: New Insights and Therapeutic Opportunities and Neural Environment ...
RESEARCH NEWS 2019-07-16 Research News Two recent papers detail stumbles and strides for tau models. In the June 6 Nature Communications, scientists led by Michael Koob and Karen Ashe, University of Minnesota, Minneapolis, reported that most of the rampant neurodegeneration seen ...
CONFERENCE COVERAGE 2019-07-14 Conference Coverage This is Part 2 of a two-part story. At a workshop during the 11th International Conference on HHV-6 and HHV-7, held June 23 to 26, 2019, in Quebec City, Canada, experts on human herpesviruses treated Alzheimer’s researchers to a lesson ...
CONFERENCE COVERAGE 2019-07-12 Conference Coverage The hypothesis that Parkinson’s disease could arise within the belly, not the brain, now gains support with a new mouse model. Valina Dawson of Johns Hopkins University, Baltimore, reported at a joint symposium held June 16-21 in ...
RESEARCH NEWS 2019-07-12 Research News The Alzheimer’s field was dealt another body blow yesterday with the announcement of a premature end to testing of Novartis/Amgen’s BACE inhibitor CNP520, aka umibecestat, in two Phase 2/3 trials. Part of the Alzheimer’s Prevention ...
